Inogen, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2026

RSU activity for the three months ended March 31, 2026 is summarized below:


										Weighted-
										average
										grant
				Performance						date fair
				and						value
Restricted stock units	Time-based			time-based			Total			per share
Unvested restricted stock units as of December 31, 2025		1,494,415			1,177,278			2,671,693		$	8.58
Granted		446,835			548,250			995,085			6.60
Vested		(390,151	)		(70,607	)		(460,758	)		8.74
Forfeited/canceled		(81,023	)		(148,805	)		(229,828	)		9.01
Unvested restricted stock units as of March 31, 2026 (1)		1,470,076			1,506,116			2,976,192		$	7.86
Unvested and expected to vest restricted stock units outstanding as of March 31, 2026								1,982,227		$	7.80

(1) Outstanding RSUs are based on the maximum payout of the targeted number of shares.

Summary of Stock-based Compensation Expense

Stock-based compensation expense recognized for the three months ended March 31, 2026 and 2025, was as follows:


	Three months ended
	March 31,
	2026		2025
Stock-based compensation expense by type of award:
Restricted stock units	$	1,864	$	2,008
Employee stock purchase plan		86		139
Total stock-based compensation expense	$	1,950	$	2,147

For the three months ended March 31, 2026 and 2025, respectively, stock-based compensation expense recognized under ASC 718, included in cost of revenue, research and development expense, sales and marketing expense, and general and administrative expense was as follows:


	Three months ended
	March 31,
	2026		2025
Cost of revenue	$	182	$	167
Research and development		151		95
Sales and marketing		39		214
General and administrative		1,578		1,671
Total stock-based compensation expense	$	1,950	$	2,147